Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12544395 | 1.00 | HTR2C (0.50) | HTR2CHTR2ACDC7CDK2ROCK1 | |
| SCHEMBL29174324 | 0.87 | HTR2C (0.44) | HTR2CHTR2ACDC7CDK2ROCK1 | |
| SCHEMBL29174304 | 0.86 | AHR (0.54) | HTR2CHTR2ACDC7CDK2ROCK1 | |
| SCHEMBL850727 | 0.86 | HTR2C (0.50) | HTR2CHTR2ASLC6A2SLC6A4MAPT | |
| SCHEMBL16937932 | 0.81 | HTR2A (0.49) | HTR2CHTR2AROCK1HTR7MAPT | |
| SCHEMBL22717788 | 0.81 | HTR2C (0.49) | HTR2CHTR2AP2RX7NPY5R | |
| SCHEMBL1956343 | 0.79 | HTR2C (0.41) | HTR2CHTR2ACDC7CDK2HTR7 | |
| SCHEMBL917628 | 0.79 | PRKCI (0.41) | HTR2CHTR2ASLC6A2SLC6A4MAPT | |
| SCHEMBL516662 | 0.79 | HTR7 (0.40) | HTR2CHTR2ACDC7CDK2HTR7 | |
| SCHEMBL916893 | 0.77 | HTR6 (0.42) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| CN-116836157-A | Oxadiazole derivative and preparation method and application thereof | 星希尔生物科技(上海)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023060362-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | HTR2C 4341/4885HTR2A 4146/4885CDC7 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.